PMID- 38148417
OWN - NLM
STAT- MEDLINE
DCOM- 20240111
LR  - 20240112
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Print)
IS  - 1523-3804 (Linking)
VI  - 26
IP  - 1
DP  - 2024 Jan
TI  - Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes.
PG  - 1-10
LID - 10.1007/s11883-023-01181-4 [doi]
AB  - PURPOSE OF REVIEW: To highlight that body fat depletion (the Yin paradigm) with 
      glucose-lowering treatments (the Yang paradigm) are associated with metabolic 
      benefits for patients with type 2 diabetes mellitus (T2DM). RECENT FINDINGS: The 
      sodium-glucose cotransporter-2 inhibitor-mediated sodium/glucose deprivation can 
      directly improve glycemic control and kidney outcome in patients with T2DM. The 
      glucose deprivation might also promote systemic fatty acid beta-oxidation to deplete 
      ectopic/visceral fat and thereby contribute to the prevention of cardiovascular 
      diseases. As with metabolic surgery, bioengineered incretin-based medications 
      with potent anorexigenic and insulinotropic efficacy can significantly reduce 
      blood glucose as well as body weight (especially in the ectopic/visceral fat 
      depots). The latter effects could be a key contributor to their 
      cardiovascular-renal protective effects. In addition to a healthy diet, the newer 
      glucose-lowering medications, with body fat reduction effects, should be 
      prioritized when treating patients with T2DM, especially for those with 
      established cardiovascular/renal risks or diseases.
CI  - (c) 2023. The Author(s).
FAU - Zhu, Jingjing
AU  - Zhu J
AD  - Department of Endocrinology and Metabolism, the Second Affiliated Hospital of 
      Soochow University, Suzhou, Jiangsu, People's Republic of China.
AD  - Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and 
      Medical Sciences, University of Liverpool, Liverpool, UK.
AD  - Clinical Sciences Centre, Liverpool University Hospitals NHS Foundation Trust, 
      Longmoor Lane, Liverpool, UK.
FAU - Wilding, John P H
AU  - Wilding JPH
AD  - Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and 
      Medical Sciences, University of Liverpool, Liverpool, UK. 
      j.p.h.wilding@liverpool.ac.uk.
AD  - Clinical Sciences Centre, Liverpool University Hospitals NHS Foundation Trust, 
      Longmoor Lane, Liverpool, UK. j.p.h.wilding@liverpool.ac.uk.
LA  - eng
GR  - SDFEYBS1815/Second Affiliated Hospital of Soochow University/
GR  - 202006920018/China Scholarship Council/
GR  - The Jiangsu Innovation & Career Fund for PhD 2019/Government of Jiangsu Province/
PT  - Journal Article
PT  - Review
DEP - 20231227
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Hypoglycemic Agents/adverse effects
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Glucose/metabolism
MH  - Adipose Tissue/metabolism
MH  - Sodium/therapeutic use
PMC - PMC10776473
OTO - NOTNLM
OT  - Body fat
OT  - Incretin
OT  - Metabolic benefit
OT  - Sodium-glucose cotransporter-2 inhibitor
OT  - Type 2 diabetes
COIS- Conflicts of Interest: Professor Wilding reports grants and personal fees from 
      AstraZeneca; personal fees and consultancy fees paid to his institution from 
      Boehringer Ingelheim; grants; personal fees and consultancy paid to his 
      institution from Novo Nordisk; consultancy fees paid to his institution from 
      Altimmune, Eli Lilly, Menarini, Napp, Pfizer, Rhythm Pharmaceuticals, Saniona, 
      Tern, Shionogi, and Ysopia, outside the submitted work. Dr. Zhu reports no 
      conflict of interest.
EDAT- 2023/12/27 00:41
MHDA- 2024/01/11 07:42
PMCR- 2023/12/27
CRDT- 2023/12/26 23:19
PHST- 2023/12/04 00:00 [accepted]
PHST- 2024/01/11 07:42 [medline]
PHST- 2023/12/27 00:41 [pubmed]
PHST- 2023/12/26 23:19 [entrez]
PHST- 2023/12/27 00:00 [pmc-release]
AID - 10.1007/s11883-023-01181-4 [pii]
AID - 1181 [pii]
AID - 10.1007/s11883-023-01181-4 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2024 Jan;26(1):1-10. doi: 10.1007/s11883-023-01181-4. Epub 
      2023 Dec 27.